Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24674803 | 1.00 | MEN1 (0.45) | MEN1KMT2ACASP2GLP1RSMN1; SMN2 | |
| SCHEMBL19491599 | 0.89 | MEN1 (0.46) | MEN1KMT2ACASP2GLP1RSMN1; SMN2 | |
| SCHEMBL25976736 | 0.88 | MEN1 (0.45) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL22909325 | 0.87 | MEN1 (0.47) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL25546664 | 0.87 | MEN1 (0.47) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL24700122 | 0.87 | CASP2 (0.44) | MEN1KMT2ACASP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL22526369 | 0.87 | MEN1 (0.47) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL24673572 | 0.87 | CASP2 (0.54) | CASP2GLP1R | |
| SCHEMBL10048529 | 0.85 | CASP2 (0.55) | MEN1KMT2ACASP2CA12CA1 | |
| SCHEMBL24470294 | 0.84 | MEN1 (0.45) | MEN1KMT2AGLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | MEN1 3175/4885KMT2A 1513/4885CASP2 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.